Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912461 | 0.88 | CYP1A2 (0.35) | CYP1A2HPGDCD274ALDH1A1GAA | |
| SCHEMBL319862 | 0.81 | ALDH1A1 (0.37) | CYP1A2HPGDCD274ALDH1A1RAB9A | |
| SCHEMBL5578038 | 0.80 | HCAR3 (0.33) | CYP1A2HPGDCD274ALDH1A1RAB9A | |
| SCHEMBL15465348 | 0.80 | SLC18A3 (0.32) | ABL1MEN1KMT2A | |
| SCHEMBL15465350 | 0.80 | SLC18A3 (0.32) | ABL1MEN1KMT2A | |
| SCHEMBL15465140 | 0.79 | SLC18A3 (0.31) | ABL1MEN1KMT2A | |
| SCHEMBL15465141 | 0.79 | SLC18A3 (0.31) | ABL1MEN1KMT2A | |
| SCHEMBL17610374 | 0.78 | ATR (0.35) | CD274ALDH1A1RAB9AATRABL1 | |
| SCHEMBL16057242 | 0.78 | CD274 (0.33) | CD274ATRABL1 | |
| SCHEMBL18946120 | 0.78 | GAA (0.36) | CD274ALDH1A1RAB9AGAAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8598200-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073143-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | CYP1A2 3189/4885HPGD 3911/4885CD274 4726/4885 |
| US-20120302599-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | CYP1A2 3189/4885HPGD 3911/4885CD274 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.